AgingResearch.NewsJoin free

Ascidian Therapeutics

CompanyUnited States

Ascidian Therapeutics develops one asset, in phase 1 (ACDN-01 in cone rod dystrophy). Mostly gene therapy acting on ABCA4; based in the United States.

1
Asset
Furthest
Phase 1
1
Trial
0
Signals

Pipeline

1

  • ACDN-01

    RNA exon editing therapy to replace mutated ABCA4 exons.

    Phase 1, Gene therapy, ABCA4, cone rod dystrophy, juvenile macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1

Updated 8 Oct 2026 · 2 sources

Intelligence